Please assess the completion status of the following clinical trial:

Trial Title: Oral Pilocarpine in the Treatment of the Dry Eye of Patients With Sjogrens Syndrome

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients with Sjögren's syndrome, both in primary and secondary forms, whose diagnoses were established according to the criteria defined by the - American-European Consensus for the diagnosis of Sjögren's syndrome.~* Patients with the secondary form of the syndrome, collagen disease considered controlled by a rheumatologist, before the start of the trial and stable until the end of the study.~* Systemic therapy instituted up to two months before the beginning of the protocol.~* Literate patients.~* Signature of the informed consent form~Exclusion Criteria:~* Eye or eyelid surface disease not attributed to Sjogren's syndrome.~* Temporary or permanent occlusion of tear points.~* Use of contact lenses.~* Use of systemic medication that is known to influence tear flow.~* Need to modify the systemic treatment of the underlying disease during the trial.~* Pregnancy or breastfeeding.~* Known hypersensitivity reaction to pilocarpine hydrochloride.~* Severe cardio-pulmonary disease.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Pilocarpine Hydrochloride (Type: EXPERIMENTAL): Patients with Sjögren's syndrome were allocated to receive oral pilocarpine 20mg per day, (5mg every 6 hours, for ten weeks.
- placebo (Type: PLACEBO_COMPARATOR): Patients with Sjögren's syndrome were allocated to receive placebo administered in the same way (1 tablet every 6 hours), for ten weeks

Based on this trial design, predict the completion outcome and termination type (if applicable).